We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Immunomedics Inc | NASDAQ:IMMU | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 87.86 | 88.00 | 83.47 | 0 | 01:00:00 |
17 November 2017
Immunicum AB (publ): Interim Report Q3 - Corporate Update and OutlookImmunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing an off-the-shelf immune system primer against a range of solid tumors, today announced its financial results and a corporate update for the third quarter 2017.
CEO Comment - Third quarterOur vision as a Company is to advance ilixadencel as a novel therapy for the treatment of solid tumors and to continue the strategic development of our pipeline to build long-term value for our shareholders. This past quarter and the weeks up until this report have been particularly exciting because we have achieved several scientific and clinical milestones and initiated a financial transaction to support our vision and long-term success.
Most importantly, we completed the HCC Phase I/II clinical study with positive safety and tolerability results as well as encouraging immune system activation data. Beyond the positive clinical data, we were pleased to announce the presentation of preclinical ilixadencel mode of action data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting .
Looking forward, we have announced with our Board of Directors a Rights Issue that will support the ongoing operations and allow the Company to implement the next phase of our updated clinical development plan. We designed this plan with a clear focus on increasing the opportunities for ilixadencel in the evolving cancer therapeutic landscape based on its applicability in a variety of solid tumors, its potential synergistic effects with other cancer therapies and its encouraging safety profile. In order to minimize shareholder dilution while maximizing value creation for the Company and ilixadencel, Immunicum's management and board made the decision to finance the plan in stages. The secured proceeds from the announced Rights Issue will ensure that the Company and its ongoing projects are fully financed until completion in 2019, while also providing valuable data in combination with checkpoint inhibitors in three interesting new indications, advancing ilixadencel's potential on multiple fronts. While we still believe that HCC represents a very attractive indication where ilixadencel could make a significant impact to existing treatment, we also believe that it is important for the Company to reach its key value inflection points. Therefore, we will stay focused on achieving those milestones in the near-term and remain open to strategic options that could support a Phase II trial in HCC. The proceeds from the announced Rights Issue will allow us to concentrate on fulfilling ilixadencel's potential in multiple indications and combinations, while simultaneously taking the Company to the next stage of its development. Speaking for the management team, all of whom will participate in the Rights Issue, and as a company, we are committed to the opportunity before us to build value for our shareholders and bring innovative treatments to patients.
Carlos de Sousa
President and CEO
Significant events during the third quarterThird quarter (July-September) 2017 compared with the same period in 2016
The period January-September 2017 compared with the same period in 2016
The full quarterly report is available on:
http://immunicum.se/investors/financial-reports/
The information is such information that Immunicum is obliged to make public pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the company's contact person on November 17, 2017 at 08.00 CET.
For more information, please contact:Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: ir@immunicum.com
MacDougall Biomedical Communications
Joanne Tudorica
Telephone: +49 89 2424 3494
E-mail: ir@immunicum.com
The Company's Certified Adviser is Redeye AB
Telephone: +46 (0)8 545 013 30
www.redeye.se
About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq First North Premier. www.immunicum.com |
1 Year Immunomedics Chart |
1 Month Immunomedics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions